Ran Nussbaum - Mar 25, 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Mar 25, 2021
Transactions value $
$11,055
Form type
4
Date filed
6/9/2021, 01:42 PM
Previous filing
Nov 30, 2022
Next filing
May 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise $11.1K +2.21K +0.15% $5.00* 1.43M Mar 25, 2021 Managing Partner of entities affiliated with Pontifax Management III G.P.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Options Exercise $0 -2.21K -100% $0.00* 0 Mar 25, 2021 Common Stock 2.21K $5.00 by Pontifax (Israel) III Limited Partnership
transaction URGN Stock Option (right to buy) Award $0 +6.82K $0.00 6.82K Jun 7, 2021 Common Stock 6.82K $17.89 by Pontifax (Israel) III Limited Partnership F1
transaction URGN Stock Option (right to buy) Award $0 +3.18K $0.00 3.18K Jun 7, 2021 Common Stock 3.18K $17.89 By Pontifax Cayman III Limited Partnership F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year.